KX-826 Phase III Clinical Trial Achieves Milestone Success; New Drug Application Submitted

KX-826 Clinical Results (KOSHINÉ)

📊 Clinically Demonstrated Efficacy

• Shown to significantly improve hair regrowth in a multicenter, randomized, double-blind, vehicle-controlled clinical study

• Consistent results observed across multiple dose groups, indicating stable and reproducible efficacy

• Achieved statistically significant improvement versus vehicle (control) group

• Demonstrated sustained efficacy in both male and female subjects with androgenetic alopecia (AGA)

🛡 Favorable Safety Profile

• Well-tolerated overall, with no treatment-related serious adverse events (SAEs) reported

• Adverse event rates were comparable to the control group

• Designed for topical scalp application with minimal systemic exposure

• Supported by favorable tolerability in clinical evaluation, including longer-term use trends

🧬 Mechanism of Action

• A topical androgen receptor (AR) antagonist

• Works by blocking androgen receptor activation in hair follicles

• Helps reduce follicular miniaturization associated with AGA

• Supports a healthier scalp environment and normal hair growth cycle

• Localized scalp activity helps minimize systemic side effects

🌍 Clinical Overview

• Supported by multiple clinical studies conducted in China and the United States

• Represents a next-generation topical approach for androgenetic alopecia (AGA)

• Designed to complement existing standard hair loss treatment options

✨ KOSHINÉ Product Positioning

• KOSHINÉ KX-826 Series is developed based on the same core active compound and mechanism evaluated in clinical studies

• Formulated to deliver consistent topical application experience aligned with clinically studied ingredient behavior

• Designed to support visible hair density improvement and scalp health maintenance in real-world use conditions

Clinically Proven Results from Phase III Trials

 Data sourced from officially published clinical study results.